Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.67 |
| ▸ | CTSK | P43235 | 6/20 | 0.67 |
| ▸ | NOS2 | P35228 | 6/20 | 0.58 |
| ▸ | NOS3 | P29474 | 3/20 | 0.58 |
| ▸ | NOS1 | P29475 | 3/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479104 | 1.00 | CTSS (0.67) | CTSSCTSKNOS2NOS3NOS1 | |
| SCHEMBL25382593 | 1.00 | CTSS (0.67) | CTSSCTSKNOS2NOS3NOS1 | |
| SCHEMBL2108340 | 0.93 | CTSS (0.68) | CTSSCTSKNOS2NOS3NOS1 | |
| SCHEMBL2108343 | 0.93 | CTSS (0.68) | CTSSCTSKNOS2NOS3NOS1 | |
| SCHEMBL3499367 | 0.91 | CTSS (0.57) | CTSSCTSKNOS2NOS3NOS1 | |
| SCHEMBL2479479 | 0.91 | CTSS (0.66) | CTSSCTSKNOS2NOS3NOS1 | |
| SCHEMBL3499368 | 0.91 | CTSS (0.57) | CTSSCTSKNOS2NOS3NOS1 | |
| SCHEMBL22962369 | 0.91 | CTSS (0.66) | CTSSCTSKNOS2NOS3NOS1 | |
| SCHEMBL27477981 | 0.91 | CTSS (0.57) | CTSSCTSKNOS2NOS3NOS1 | |
| SCHEMBL16459725 | 0.88 | CTSS (0.63) | CTSSCTSKNOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023165334-A1 | KETO AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | 成都威斯克生物医药有限公司 | 2023-09-07 | — | — | WO | disclosed |
| CN-116693447-A | Ketone amide derivative and pharmaceutical application thereof | 成都威斯克生物医药有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20220169581-A1 | DIRECT AROMATIC CARBON-OXYGEN AND CARBON-HYDROGEN BOND FUNCTIONALIZATION VIA ORGANIC PHOTOREDOX CATALYST | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2022-06-02 | — | — | US | disclosed |
| US-10385007-B2 | Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180162802-A1 | MONAMINE AND MONOAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162802-A1 | MONAMINE AND MONOAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
| WO-2018107158-A1 | MONAMINE AND MONOAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2265601-B1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | disclosed |
| CN-102026996-A | Pyridazine derivatives as factor XIA inhibitors | BRISTOL MYERS SQUIBB CO | 2011-04-20 | — | — | CN | disclosed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| EP-2265601-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009114677-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385007-B2 | Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, MAOB, LTB4R | CTSS 167/4885CTSK 245/4885NOS2 599/4885 |
| US-20180162802-A1 | MONAMINE AND MONOAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, MAOB, LTB4R | CTSS 167/4885CTSK 245/4885NOS2 599/4885 |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | F11, F12, TFPI2 | CTSS 541/4885CTSK 273/4885NOS2 2797/4885 |
| US-20220169581-A1 | DIRECT AROMATIC CARBON-OXYGEN AND CARBON-HYDROGEN BOND FUNCTIONALIZATION VIA ORGANIC PHOTOREDOX CATALYST | PPOX, CYCS, SCO2 | CTSS 899/4885CTSK 1746/4885NOS2 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.